Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hannah Daniel

Having recently joined the team in 2022, Hannah Daniel is a consumer health reporter for Pharma Intelligence’s Health, Beauty, and Wellness publication.

Latest From Hannah Daniel

Prevacid 24HR First OTC PPI With Skin Reaction Warning

Lansoprazole along with other OTC and Rx PPI ingredients were linked to a potential risk of acute generalized exanthematous pustulosis FDA in 2019 found a trend in adverse event reports.

FDA Drug Safety

After 10 Years, US FDA ‘Additional Conditions’ Proposed Rule Offers ‘Novel Switch’ Pathway

Publication of "ACNU" proposed rule wasn’t reached in a straight line and featured coining another term with a more of a regulatory sound, “NSURE.” The proposed rule also detours on explaining where the agency wouldn’t steer OTC drug manufacturing and marketing.

Prescription To OTC Switch Drug Approval Standards

Over the Counter 29 June 2022: OTC Birth Control In The Wake Of The US Supreme Court Decision With Victoria Nichols

In this episode, HBW Insight speaks to Victoria Nichols, project director of Free the Pill, a campaign supporting increased OTC oral contraceptive access in the US. In the wake of the Supreme Court’s decision to overturn Roe v. Wade on 24 June, Nichols discusses the importance of advocating for OTC birth control, the limited availability of OTC oral contraceptives in the US, and the current legislation being introduced that would help ensure OTC birth control is covered by insurance. 

United States OTC Drugs

After 10 Years, US FDA ‘Additional Conditions’ Proposed Rule Offers ‘Novel Switch’ Pathway

Publication of "ACNU" proposed rule wasn’t reached in straight line and featured coining another term with more of a regulatory sound, “NSURE,” and detours on explaining where the agency wouldn’t steer OTC drug manufacturing and marketing.

FDA Prescription To OTC Switch

USPSTF Doesn’t See Forest Of VMS Benefits For Trees Of Reducing Cancer, Heart Disease Risks

US Preventative Services Task Force concludes evidence doesn't support  recommending VMS use to prevent cancer or cardiovascular disease. Trade groups and a natural medicine expert say task force's focus is narrow and its recommendation misleading. 

Dietary Supplements Research & Development

CHPA Adds Pavlick, Miller In Director Posts

Larisa Pavlick joins senior director of quality assurance and technical affairs, and Kirby Miller as director of federal government affairs.

Executive Changes Companies
See All
UsernamePublicRestriction

Register